Lundin Law PC announces a class action lawsuit has been filed against Tetraphase Pharmaceuticals, Inc. ("Tetraphase" or the "Company") (NASDAQ: TTPH) concerning possible violations of federal securities laws between March 5, 2015 and September 8, 2015. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the March 28, 2016, lead plaintiff motion deadline. To participate in this class action lawsuit, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via e-mail at email@example.com. According to the complaint, the Company issued materially false and misleading statements to investors regarding the efficacy and safety of Eravacycline, and its capacity for approval by both the U.S. Food and Drug Administration ("FDA") and the European Medicines Agency ("EMA"). No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member. Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.